FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction
Pharmaceutical Business Review
MARCH 11, 2024
This label expansion follows a supplemental New Drug Application (sNDA) submitted by the company. The study, which was initiated in 2018, enrolled 17,604 adults across 41 countries to assess the efficacy of semaglutide 2.4mg in comparison to placebo as an adjunct to standard of care for MACE prevention.
59 
Let's personalize your content